Drugs / ODACTRA
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT05113394 | Feb 2027 → Feb 2028 | allergic disease, asthma | Boston Children's Hospital | Withdrawn | No outcome recorded Stop: Business |
| Comparator or background therapy1 trial | ||||||
| Phase 4 | NCT04100902 Comparator | Jan 2020 → Feb 2022 | allergic asthma | Bispebjerg Hospital | Completed | No outcome recorded |
Press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-03-07 | ALK-Abelló A/S | ACARIZAX® approved in Canada for treatment of young children alk.net ↗ |
| 2025-02-27 | ALK-Abelló A/S | FDA approves ODACTRA® for the treatment of house dust mite allergy in young children alk.net ↗ |
| 2024-12-12 | ALK-Abelló A/S | ACARIZAX® approved in Europe for treatment of young children alk.net ↗ |
| 2017-08-21 | ALK-Abelló A/S | ALK to accelerate launches of ODACTRA™ in the USA / ACARIZAX® in Canada alk.net ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Odactra | “HDM-SLIT tablet (Odactra®/Acarizax®) is a rapidly dissolving, freeze-dried, oral lyophilizate for oromucosal treatment, which contains a 1:1 mixture of two allergen extracts...” NCT05113394 ↗ |
| Known as | Acarizax | “HDM-SLIT tablet (Odactra®/Acarizax®) is a rapidly dissolving, freeze-dried, oral lyophilizate for oromucosal treatment, which contains a 1:1 mixture of two allergen extracts...” NCT05113394 ↗ |